Biogen Idec (BIIB) to Present Positive Five-Year ENDORSE Phase 3 Data
Tweet Send to a Friend
Biogen Idec (Nasdaq: BIIB) announced that five-year results from the ENDORSE Phase 3 extension study show TECFIDERA (dimethyl fumarate) provides ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
